

May 2, 1966

Mr. Robert C. Zwahlen
Medical Liaison Staff
Clinical Investigation Department
Smith, Kline and French Laboratories
1500 Spring Garden Street
Philadelphia, Pennsylvania 19101

Dear Bob:

I should like to bring you up to date on the SKF study of dose response characteristics of different doses of amobarbital and dextroamphetamine. As you know, the data collection phase has been in progress for more than five months. As of this date, ten subjects are now complete, and there are an additional six subjects who are in process. These subjects require twelve additional records, but insofar as one required four, it will take four weeks to be complete, and it is my expectation that all the data will be collected by the end of May.

Data analyses will begin promptly and it is our expectation that we will be able to complete the analyses during the summer, barring any unforeseen statistical or analytic problems.

As you know, I will be moving to the New York Medical College early in June. Despite this transfer, it is my intention to complete this SKF study and to do so, any data analyses that are not completed here will be completed in New York. I will personally accept the responsibility for the write-up and the presentation of the material.

My address in New York will be:

Department of Psychiatry
New York Medical College
5th Avenue and 106th Street
New York, New York 10029

I will also be spending part of my time at the Metropolitan Hospital. If you wish to reach me during the next few months, please call St. Louis and my secretary will tell you where I am. My number at Metropolitan Hospital is ENright 9-6300, Ext. 720 (708). At the University, the number is 876-5500, Ext. 455. (That is the Chairman's number, and his secretary will usually know where I am or will be able to take a message for me until I have my own secretary.)

Mr. Zwahlen (continued)

Thank you for the invitation to visit you in Atlantic City. You must know that I have enjoyed our relationship very much, and I hope that the data will warrant your faith in our work. I do look forward to continuing to work with SKF and specifically with Don Cheatham. You may be interested to know that one of my responsibilities is to establish an Early Clinical Drug Evaluation Unit with both in-patient and out-patient facilities. I hope that I can accomplish there what I have tried to accomplish here, and look forward to our continued collaboration.

My best regards.

Very sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:jmh